{"entity":{"id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","aka":[],"tldr":"A phase 1/2 trial of DZD8586 in diffuse large b-cell lymphoma, run by Dizal Pharmaceuticals, now recruiting.","summary":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) is a phase 1/2 interventional study registered as NCT07059650 by Dizal Pharmaceuticals, with 150 participants planned, started 2025-08-19 and due to reach its primary completion in 2030-10. Interventions recorded: DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07059650","url":"https://clinicaltrials.gov/study/NCT07059650"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["dzd8586"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07059650","phase":"1/2","setting":"A Phase Ib/II, Multicenter Study to Evaluate the Efficacy and Safety of DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma","sponsor":"Dizal Pharmaceuticals","enrolled":150,"outcomes":[]},"route":"/trials/nct07059650/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}